222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04009668October 2, 20192/7/2019Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseasePrecision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseFSGS;MCD;Focal Segmental Glomerulosclerosis;Minimal Change DiseaseDrug: adalimumabUniversity of MichiganNew York UniversityRecruiting6 Years70 YearsAll8Phase 2United States
2NCT00814255December 200822/12/2008Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed1 Year65 YearsAll32Phase 2United States;Canada
3NCT00193648July 200510/9/2005Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)Novel Therapies for Resistant FSGSFocal GlomerulosclerosisDrug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira)North Shore Long Island Jewish Health SystemUniversity of North Carolina;The Cleveland ClinicCompleted2 Years40 YearsBoth21Phase 1United States